104 related articles for article (PubMed ID: 10025882)
21. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis.
Hirota C; Iida M; Aoyagi K; Matsumoto T; Tada S; Yao T; Fujishima M
Cancer; 1996 Oct; 78(8):1660-5. PubMed ID: 8859177
[TBL] [Abstract][Full Text] [Related]
22. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors.
Giardiello FM; Offerhaus JA; Tersmette AC; Hylind LM; Krush AJ; Brensinger JD; Booker SV; Hamilton SR
Gut; 1996 Apr; 38(4):578-81. PubMed ID: 8707091
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal analysis of colon crypt stem cell dynamics in sulindac treated Familial Adenomatous Polyposis patients.
Ma H; Brosens LAA; Elias SG; Morsink FHM; Nijman IJ; Hylind LM; Montgomery EA; Offerhaus GJA; Giardiello FM; de Leng WWJ
Sci Rep; 2017 Sep; 7(1):11972. PubMed ID: 28931879
[TBL] [Abstract][Full Text] [Related]
24. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
[TBL] [Abstract][Full Text] [Related]
25. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis.
Matsumoto T; Nakamura S; Esaki M; Yao T; Iida M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):251-7. PubMed ID: 16460482
[TBL] [Abstract][Full Text] [Related]
26. Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis.
Friederich P; Verschuur J; van Heumen BW; Roelofs HM; Berkhout M; Nagtegaal ID; van Oijen MG; van Krieken JH; Peters WH; Nagengast FM
Int J Colorectal Dis; 2011 May; 26(5):575-82. PubMed ID: 21243500
[TBL] [Abstract][Full Text] [Related]
27. Sulindac therapy of colorectal polyps in familial adenomatous polyposis.
Tonelli F; Valanzano R; Dolara P
Dig Dis; 1994; 12(5):259-64. PubMed ID: 7882547
[TBL] [Abstract][Full Text] [Related]
28. Combinatorial chemoprevention of intestinal neoplasia.
Torrance CJ; Jackson PE; Montgomery E; Kinzler KW; Vogelstein B; Wissner A; Nunes M; Frost P; Discafani CM
Nat Med; 2000 Sep; 6(9):1024-8. PubMed ID: 10973323
[TBL] [Abstract][Full Text] [Related]
29. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis.
Qiu W; Wang X; Leibowitz B; Liu H; Barker N; Okada H; Oue N; Yasui W; Clevers H; Schoen RE; Yu J; Zhang L
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20027-32. PubMed ID: 21041628
[TBL] [Abstract][Full Text] [Related]
30. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
31. Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis.
Marotta A; Tan C; Gray V; Malik S; Gallinger S; Sanghera J; Dupuis B; Owen D; Dedhar S; Salh B
Oncogene; 2001 Sep; 20(43):6250-7. PubMed ID: 11593435
[TBL] [Abstract][Full Text] [Related]
32. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
[TBL] [Abstract][Full Text] [Related]
33. Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?
Shureiqi I
Cancer Prev Res (Phila); 2018 Jan; 11(1):1-3. PubMed ID: 29263155
[TBL] [Abstract][Full Text] [Related]
34. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
[TBL] [Abstract][Full Text] [Related]
35. [Role of suindac in the treatment of familial adenomatous polyposis coli].
Landauer S; Halimi C; Caulin C; Bergmann JF
Therapie; 1999; 54(6):675-82. PubMed ID: 10709439
[TBL] [Abstract][Full Text] [Related]
36. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis.
Stoner GD; Budd GT; Ganapathi R; DeYoung B; Kresty LA; Nitert M; Fryer B; Church JM; Provencher K; Pamukcu R; Piazza G; Hawk E; Kelloff G; Elson P; van Stolk RU
Adv Exp Med Biol; 1999; 470():45-53. PubMed ID: 10709673
[TBL] [Abstract][Full Text] [Related]
37. [The effects of sulindac on the pathology of colorectal remnant polyps of familial adenomatous polyposis (FAP) patients].
Li J; Lv YM; Jin Z; Cui RL
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 37(4):371-3. PubMed ID: 16086054
[TBL] [Abstract][Full Text] [Related]
38. p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo.
Yang W; Velcich A; Mariadason J; Nicholas C; Corner G; Houston M; Edelmann W; Kucherlapati R; Holt PR; Augenlicht LH
Cancer Res; 2001 Aug; 61(16):6297-302. PubMed ID: 11507085
[TBL] [Abstract][Full Text] [Related]
39. Chemoprevention of FAP with sulindac.
Meyskens FL
Curr Oncol Rep; 2002 Nov; 4(6):463. PubMed ID: 12385292
[No Abstract] [Full Text] [Related]
40. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy.
Niv Y; Fraser GM
Gastroenterology; 1994 Sep; 107(3):854-7. PubMed ID: 8076772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
